Conclusions on Treating Carcinoid Crisis Without Perioperative Octreotide for Patients With Neuroendocrine Tumors

Name: Conclusions on Treating Carcinoid Crisis Without Perioperative Octreotide for Patients With Neuroendocrine Tumors
Uploaded: 2021-11-06T14:00:00.000Z
Description: Rodney Pommier, MD, FACS, professor of surgery, Oregon Health & Science University, provides conclusions based on the prospective study findings investigating the treatment of carcinoid crisis without perioperative octreotide.

November 6, 2021

Video

Conference|NANETS Annual Multidisciplinary NET Medical Symposium - North American Neuroendocrine Tumor Society Annual Multidisciplinary NET Medical Symposium

Rodney Pommier, MD, FACS, professor of surgery, Oregon Health & Science University, provides conclusions based on the prospective study findings investigating the treatment of carcinoid crisis without perioperative octreotide.

Pharmacy Times interviewed Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, on his presentation at the 2021 NANETS Multidisciplinary Neuroendocrine Tumors Medical Virtual Symposium discussing a prospective study of carcinoid crisis with no perioperative octreotide.

During the interview, Pommier provided conclusions based on the prospective study findings investigating the treatment of carcinoid crisis without perioperative octreotide.